Ministry supports expanding areas for third-phase trials of Nanocovax

Illustrative image (Photo: VNA)

Hanoi (VNA) – has said his ministry supports the expansion of
areas eligible for the third phase of clinical trials of Nanocovax, a product of Nanogen Pharmaceutical
Biotechnology JSC based on recombinant DNA/protein technology.

The work must ensure safety and feasibility,
he said.

Earlier, the vaccine underwent the
first-phase test from December 18, 2020, the second phase from February 26,
2021 and the third phase from June 11, 2021.

According to the approved plan, the
third-phase trials aim to assess the vaccine’s efficacy and is carried out in
many centres worldwide with 13,000 volunteers.

Earlier, Deputy Prime Minister Pham Minh
Chinh asked the Health Minister to direct the use and licensing of Nanocovax with
less administrative procedures and in line with regulations.

At
a nationwide teleconference between the Government and businesses, ministries,
agencies and localities, Chinh underlined three major contents of vaccine
strategy, including importing as many as vaccines possible at the earliest.

Amid
the global shortage of vaccines, the country strives to access them via
different channels, including stepping up vaccine diplomacy, he said./.